BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37015847)

  • 1. High-dose-rate brachytherapy at 3 Gy per fraction for lip carcinoma: Treatment outcomes and toxicity at 5-years.
    Tuček L; Sirák I; Hodek M; Kašaová L; Grepl J; Paluska P; Pohanková D; Hruška L; Vošmik M; Petera J
    Brachytherapy; 2023; 22(4):496-502. PubMed ID: 37015847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
    Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
    Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
    Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
    Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose-rate versus low dose-rate brachytherapy for lip cancer.
    Ghadjar P; Bojaxhiu B; Simcock M; Terribilini D; Isaak B; Gut P; Wolfensberger P; Brömme JO; Geretschläger A; Behrensmeier F; Pica A; Aebersold DM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1205-12. PubMed ID: 22099044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose-rate brachytherapy using molds for lip and oral cavity tumors.
    Unetsubo T; Matsuzaki H; Takemoto M; Katsui K; Hara M; Katayama N; Waki T; Kanazawa S; Asaumi J
    Radiat Oncol; 2015 Apr; 10():81. PubMed ID: 25888772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose rate interstitial brachytherapy for early stage lip cancer using customized dental spacer.
    Masui K; Yamazaki H; Suzuki G; Shimizu D; Kawabata K; Noguchi N; Takenaka T; Yoshida K; Murakami N; Naito M; Yamamoto T; Kanamura N; Komori S; Oshita A; Asai J; Yamada K
    J Radiat Res; 2020 May; 61(3):506-510. PubMed ID: 32266411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
    Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
    Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
    Valduvieco I; Rovirosa Á; Herreros A; Romera I; Ríos I; Ascaso C; Sánchez-Reyes A; Arenas M; Pahisa J; Biete A
    Clin Transl Oncol; 2013 Aug; 15(8):602-7. PubMed ID: 23263910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial high-dose-rate brachytherapy in eyelid cancer.
    Mareco V; Bujor L; Abrunhosa-Branquinho AN; Ferreira MR; Ribeiro T; Vasconcelos AL; Ferreira CR; Jorge M
    Brachytherapy; 2015; 14(4):554-64. PubMed ID: 25959364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
    Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
    Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
    Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nineteen-year single-center experience in 76 patients with penile cancer treated with high-dose-rate brachytherapy.
    Kellas-Ślęczka S; Białas B; Fijałkowski M; Wojcieszek P; Szlag M; Cholewka A; Wesołowski M; Ślęczka M; Krzysztofiak T; Larysz D; Kołosza Z; Trzaska K; Pruefer A
    Brachytherapy; 2019; 18(4):493-502. PubMed ID: 31101437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
    Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
    Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma.
    Ren Y; Zhao Q; Liu H; Huang Y; Wang Z; Cao X; Teh BS; Wen B
    BMC Cancer; 2014 Nov; 14():894. PubMed ID: 25432818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate brachytherapy in uterine cervical carcinoma.
    Patel FD; Rai B; Mallick I; Sharma SC
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):125-30. PubMed ID: 15850912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.